Li Yang Pharmaceutical

Chongqing Liyang Pharmaceutical Development Co., Ltd.

86-023-86502492

language

Liyang

Blog

—

Home

Biopharmaceutical Industry: A Powerful Innovation Engine Driving Global Market Competition

The deep integration of artificial intelligence technology has transformed drug development from "searching for a needle in a haystack" to "precise navigation."

2025

10-24

The Differences Between Intermediates, Active Pharmaceutical Ingredients (APIs), Excipients, and Preparations

Intermediate, a material generated during the active pharmaceutical ingredient (API) manufacturing process that requires further molecular transformation or purification before it can be finalized as an API.

2025

09-10

What are the differences between active pharmaceutical ingredients and finished dosage forms?

Active pharmaceutical ingredients (APIs) are the active components of drugs and cannot be used directly for clinical treatment. Pharmaceutical preparations, on the other hand, are drug formulations made by processing APIs with excipients, ready for direct use by patients.

2025

07-08

The method of decocting traditional Chinese medicine

First, pour the medicinal herbs into the decoction vessel and add cool water until the herbs are fully submerged. Allow them to soak for about an hour, enabling the traditional Chinese medicine to absorb moisture thoroughly and return to a fresh state. This process ensures that the active ingredients can be released more quickly and efficiently.

2025

06-04

What are the common types of liquid formulations?

This is a common type of liquid formulation, referring to a homogeneous system in which the drug is uniformly dispersed in the solvent in molecular or ionic form.

2025

05-30

Trends in the Pharmaceutical Industry

Breakthroughs in biotechnology and artificial intelligence are driving advancements in new drug development, paving the way for more innovative therapies and offering patients a wider range of treatment options.

2025

03-18

The Difference Between Traditional Chinese Medicine Preparations and Patent Chinese Medicines

The essential differences between traditional Chinese medicine preparations and proprietary Chinese medicines lie in their preparation methods, scope of application, and approval standards.

2025

01-09

Pharmaceutical companies are actively engaged in the evaluation of generic drug consistency, and another company has successfully passed the evaluation at the start of May.

[Pharmaceutical Network Industry News] Compared to originator drugs, generic drugs have lower R&D costs and relatively less stringent approval requirements for market entry. To promote the high-quality development of generic drugs, the Generic Drug Consistency Evaluation program was introduced as a prerequisite for centralized procurement. Since the implementation of this policy, numerous pharmaceutical companies have actively participated in the evaluation process. As of May, another pharmaceutical company has announced that its drug has successfully passed the Generic Drug Consistency Evaluation. Specifically, Lissheng Pharmaceutical Co., Ltd. announced at noon on May 5th that it recently received the "Notice of Approval for Supplementary Drug Application" issued by the National Medical Products Administration for Donepezil Hydrochloride Tablets 5mg, confirming that the drug has met the standards set by the Generic Drug Consistency Evaluation program.

2022

05-06

The market for small-molecule targeted drugs is experiencing rapid growth and is expected to reach 100 billion yuan by 2025.

Small-molecule drugs currently hold significant potential in the treatment of both oncological and non-oncological diseases. In recent years, with the expansion of medical insurance coverage, the growing affordability of residents, and supportive policies aimed at fostering pharmaceutical innovation, the market for small-molecule drugs has continued to expand. As a result, an increasing number of pharmaceutical companies have accelerated their strategic investments in this promising field. For instance, recently, Hansoh Pharmaceutical Group announced that its wholly-owned subsidiary, Hansoh (Shanghai) Health, together with Jiangsu Haosen Pharmaceutical (collectively referred to as the Licensee), has entered into an exclusive licensing agreement with NiKang Therapeutics Inc. According to the agreement, the Licensee will receive an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of cancer in China, including Hong Kong, Macau, and Taiwan. The Licensee is required to pay an upfront fee of US$15 million, along with milestone payments totaling up to US$203 million contingent upon development, regulatory approval, and sales-based commercialization achievements, as well as tiered royalties based on net sales. It is worth noting that NKT2152 is a small-molecule inhibitor targeting HIF-2α, currently undergoing Phase I/II dose-escalation and expansion trials (NCT05119335). These trials are designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of the drug in patients with advanced clear-cell renal cell carcinoma (ccRCC). Industry analysts suggest that collaboration has become a common strategy among pharmaceutical companies seeking to establish a foothold in the small-molecule drug arena. Over the past few years, there has been a steady stream of announcements regarding partnerships within the industry focused on small-molecule therapies. For example, on September 8 last year, Huadong Medicine announced a collaborative partnership with Insilico Medicine to jointly accelerate the development of innovative small-molecule drugs in the oncology space. Under the terms of the agreement, Huadong Medicine and Insilico Medicine will launch new drug discovery projects through close collaboration between their respective research teams. On August 31, BiChen Pharma, a company specializing in the development of small-molecule targeted drugs capable of crossing the blood-brain barrier, announced a strategic collaboration with Sansheng National Health. Under the agreement, both parties will leverage their respective technological and resource advantages to strengthen joint efforts in developing new products and technologies. Additionally, they will collaborate extensively on the clinical development and regulatory submissions for innovative combination therapies targeting oncological indications in the Chinese market. Notably, beyond collaboration, many companies dedicated to the research and development of novel small-molecule drugs are also accelerating their fundraising activities to expedite the translation of scientific breakthroughs into tangible therapeutic advancements. For instance, on February 8 this year, Yousen Jianheng announced the successful completion of a Series A financing round exceeding RMB 200 million. This round was led by Shenzhen Fenxiang Investment, with participation from Zhangjiang HaoHeng and Yingke Capital, while existing shareholders also continued to invest. The funds raised will be utilized to advance global clinical trials for UA007 and UA021, as well as to accelerate the development of multiple small-molecule drugs targeting novel targets and innovative bispecific antibody therapies. Similarly, on February 14, Qinhao Pharma (Suzhou) Co., Ltd. (hereinafter referred to as "Qinhao Pharma") announced the successful closing of a Series B financing round valued at several hundred million RMB. Qinhao Pharma is described as a globally oriented, innovative biopharmaceutical company focused on the development of original small-molecule anti-cancer drugs. The company has already established four comprehensive drug R&D centers—covering innovative research, drug design and discovery, drug screening and evaluation, and clinical development—and has built a robust product pipeline comprising more than ten ongoing projects. Overall, as numerous pharmaceutical companies increasingly enter the small-molecule drug sector and capital continues to flow into the space, the entire market is poised for further growth and development. Earlier data from Frost & Sullivan indicated that China’s small-molecule tumor-targeted therapy market grew from RMB 8.5 billion in 2016 to RMB 37.5 billion in 2020. If current trends persist, the market is projected to reach RMB 120.5 billion by 2025 and further expand to RMB 207 billion by 2030. Against this backdrop, industry experts anticipate that companies actively engaged in this field will encounter enhanced opportunities for growth and success. **Disclaimer:** The information or opinions expressed in this article do not constitute investment advice to any individual under any circumstances.

2022

05-06

Leveraging AI to accelerate the development of innovative therapies has become a consensus among pharmaceutical companies both domestically and internationally.

Recently, Genesis Therapeutics announced a collaboration with Eli Lilly and Company to leverage Genesis's AI-driven drug discovery platform in identifying innovative therapies targeting up to five distinct targets across multiple therapeutic areas. Under the agreement, scientists from both Genesis and Eli Lilly will jointly utilize Genesis's AI platform to develop potential "first-in-class" and "best-in-class" drug candidates for three of these targets.

2022

05-06

< 1 2 > 跳转到页

National Service Hotline

86-023-86502492

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Powered By：www.300.cn SEO

Business License

Yu Public Security Network Registration No. 50010702505725